An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anaemia

摘要

Sir-Temozolomide has an excellent safety profile; however, very rarely, profound myelosuppression and aplastic anaemia after a limited exposure to temozolomide have been reported in a few reviews [1,2] and to the Food and Drug Administration's adverse event reporting system, MedWatch [3]. We evaluated the characteristics of similar haematological adverse drug reactions (ADRs) reported to the Medicines and Healthcare Products Regulatory Agency (MHRA), the regulatory authority in the UK who collate suspected ADRs spontaneously reported from healthcare professionals, members of the public, as well as industry.